Table 1.

Patient characteristics at baseline

Baseline characteristic	Natalizumab-treated patients (N = 52)
Age, years (mean [SD])	45.9 (8.80)
Female	39 (75.0)
Time from diagnosis of MS, years
0–5	22 (42.3)
6–10	14 (26.9)
11–15	13 (25.0)
≥ 16	3 (5.8)
EDSS score
Mean (SD)	2.2 (1.74)
Median (range)	2.0 (0.0–8.0)
Prior DMT treatment	40 (76.9)

Data are expressed as n (%) unless otherwise specified

DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, MS multiple sclerosis, SD standard deviation